Andrew Fein
In May 2013, Andrew Fein joined H.C. Wainwright & Co. as managing director and senior biotechnology analyst to cover companies in the biotechnology and life sciences sectors. He has 13 years of experience in healthcare and biotechnology equity research. He was previously a senior analyst at Chardan Capital Markets and held prior research positions at Jefferies & Co., Piper Jaffrey, Collins Stewart, Leerink Swann LLC and J.P. Morgan.
Recent Quotes
"ATNM's two clinical programs offer a cheap long opportunity for investors interested in AML therapeutics."
—
Andrew Fein, H.C. Wainwright & Co.
(6/2/16)
more >
"ATNM is well positioned for value with two pedigreed assets tackling two different stages of the disease."
—
Andrew Fein, H.C. Wainwright & Co.
(2/29/16)
more >
"The first clinical look at RNN's Supinoxin and RX-3117 is encouraging."
—
Andrew Fein, H.C. Wainwright & Co.
(9/29/15)
more >
"We expect RNN's oncology pipeline, led by Archexin, to come into focus by year-end."
—
Andrew Fein, H.C. Wainwright & Co.
(8/21/15)
more >
"CPXX continues to lay the groundwork for possibly becoming commercial."
—
Andrew Fein, H.C. Wainwright & Co.
(8/12/15)
more >
"We like that CPXX's approach leverages two drugs that we know work."
—
Andrew Fein, H.C. Wainwright & Co.
(6/25/15)
more >
"The next event for CPXX's CPX-351 is induction response data in Q2/15."
—
Andrew Fein, H.C. Wainwright & Co.
(3/20/15)
more >
"THLD presented data from Part C of its Phase 1/2 TH-302 study in MM."
—
Andrew Fein, H.C. Wainwright & Co.
(12/8/14)
more >
